Potential Clinical Impact of Testing for Higher Threshold of CYP2D6 Copy Number Variation

PGRN Poster (2026)

PMID

Publication AuthorsLauren Marcath, PharmD, Elizabeth Fieg, MS, CGC, Robert Rigobello, MS, CGC, Jason Chibuk, MS, CGC, Yue Zhou, PhD, Yue Wang, PhD, FACMG

Introduction

  • CYP2D6 is one of the most clinically important pharmacogenes, but also one of the most polymorphic.
    • CYP2D6 can have copy number variation (CNV), which can be impactful to function and predicted phenotype.
  • Association for Molecular Pathology joint consensus recommendation includes guidance for testing CYP2D6 CNVs but does not specify the number of copies to test for.
  • Purpose of this analysis was to determine how often distinguishing three versus four CYP2D6 copies would be clinically impactful.
image_print